Table 2.
Baseline clinical characteristics and TB incidence of HIV/AIDS patients who started ART from September 2007 to August 2008 at the University of Gondar Hospital
| Variable | Total | Incident TB+ | Incident TB- |
|---|---|---|---|
| Female sex (n[%]) | 258(64.5) | 18(69.2) | 240(64.2) |
| Age (years, mean [SD]) | 34.37 ± 9.29 | 35.4 ± 8.8 | 34.3 ± 9.3 |
| WHO HIV clinical stage (n[%]) | |||
| I | 57(14.3) | 2(3.5) | 55(96.5) |
| II | 86(21.5) | 6(7.0) | 80(93.0) |
| III | 208(52.0) | 13(6.2) | 195(93.8) |
| IV | 49(12.3) | 5(10.2) | 44(89.8) |
| CD4 count (cells/mm 3 , median [IQR]) | 152(82, 203) | 98(58,201.75) | 153(86,203) |
| CD4 count (cell/mm 3 , n[%]) | |||
| 0-99 | 127(31.8) | 13(10.4) | 112(89.6) |
| ≥100 | 170(42.5) | 13(4.7) | 262(95.3) |
| Initial ART Regimen (n[%]) | |||
| d4T/3TC/NVP or EFV | 49(12.3) | 4(8.2) | 45(91.8) |
| AZT/3TC/NVP or EFV | 189(47.3) | 15(7.9) | 174(92.1) |
| TDF/3TC/NVP or EFV | 162(40.5) | 7(4.3) | 155(95.7) |
| Functional status (n[%]) | |||
| Working | 340(85.0) | 20(5.9) | 320(94.1) |
| Ambulatory | 49(12.3) | 4(8.2) | 45(91.8) |
| Bed ridden | 11(2.8) | 2(18.2) | 9(81.8) |
d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; AZT: zidovudine; EFV: efavirenz; TDF: tenofobir; TB: tuberculosis; HIV: human immunodeficiency virus; ART: antiretroviral therapy; IQR: interquartile range; SD: standard deviation; WHO: world health organization.